Table 2 Changes in outcome measures (week 0 vs. week 1, week 0 vs. week 5) after treatment completion in patients who received Dangguixu-san or placebo for acute lateral ankle sprain (n = 23 each)
From: Effects of Dangguixu-san in patients with acute lateral ankle sprain: a randomized controlled trial
Groups | Dependent variables | Week 0 (M ± SD) | Week 1 (M ± SD) | Week 5 (M ± SD) | Difference (w1–w0) | Z (P)a | Difference (w5–w0) | Z (P)a | x2 (P)b |
|---|---|---|---|---|---|---|---|---|---|
DS group (n = 23) | Degree of edema | 0.67 ± 0.89 | 0.23 ± 0.43 | 0.21 ± 0.33 | − 0.44 ± 0.93 | − 2.57 (0.010) | − 0.45 ± 0.83 | − 2.47 (0.014) | 6.48 (0.039) |
VAS of pain | 44.87 ± 17.02 | 24.96 ± 18.27 | 12.74 ± 16.20 | − 19.91 ± 21.62 | − 3.09 (0.002) | − 32.13 ± 23.65 | −3.75 (< 0.001) | 32.89 (< 0.001) | |
TOTAL EQ-5D-5L | 10.48 ± 3.06 | 8.35 ± 2.85 | 6.70 ± 2.77 | −2.13 ± 2.69 | −3.04 (0.002) | −3.78 ± 4.22 | − 3.49 (< 0.001) | 26.42 (< 0.001) | |
TOTAL FAOS | 307.43 ± 82.19 | 368.55 ± 74.72 | 430.09 ± 79.82 | 61.13 ± 72.52 | −3.13 (0.002) | 122.66 ±107.34 | −3.65 (< 0.001) | 24.02 (< 0.001) | |
Placebo group (n = 23) | Degree of edema | 0.52 ± 0.67 | 0.27 ± 0.54 | 0.12 ± 0.44 | −0.24 ± 0.53 | −2.11 (0.035) | −0.40 ± 0.70 | −2.60 (0.009) | 8.03 (0.018) |
VAS of pain | 44.04 ± 16.49 | 19.26 ± 14.14 | 14.87 ± 12.82 | −24.78 ± 12.83 | −4.07(< 0.001) | − 29.17 ± 16.26 | −3.94 (< 0.001) | 36.56 (< 0.001) | |
TOTAL EQ-5D-5L | 10.17 ± 2.61 | 7.61 ± 1.83 | 6.65 ± 1.70 | −2.57 ± 1.78 | −3.94(< 0.001) | − 3.52 ± 2.84 | − 3.72 (< 0.001) | 32.84 (< 0.001) | |
TOTAL FAOS | 299.54 ± 76.45 | 383.45 ± 66.80 | 428.00 ± 59.18 | 83.91 ± 74.37 | −3.68(< 0.001) | 128.46 ± 85.78 | −3.83 (< 0.001) | 28.17 (< 0.001) |